J&J Settles Talcum Powder Lawsuits From States for $700 Million

Follow Drugslib on

Medically reviewed by Drugs.com.

By Robin Foster HealthDay Reporter

THURSDAY, June 13, 2024 -- Johnson & Johnson will pay $700 million to settle claims from 42 states and the District of Columbia that the company continued to market its talcum powder products even as evidence tied them to a heightened risk for cancer.

J&J did not admit to any wrongdoing in settling with the states, which were led by Florida, Texas and North Carolina.

“We have reached a landmark settlement with Johnson & Johnson ensuring that the company will abide by the law and take effective steps to protect consumers from potentially hazardous ingredients,” Texas Attorney General Ken Paxton said in a statement released Tuesday. “I’m proud to lead this coalition of 43 attorneys general to stand up for consumers’ health and truth in marketing.”

As part of the settlement, which still needs judicial approval, the company has stopped making, promoting and selling all of its products that contain talcum powder. That includes Johnson's Baby Powder and Johnson & Johnson's Shower to Shower. J&J will make four settlement payments, starting at the end of July, according to the settlement.

“This is a major advancement for consumer product safety, as Johnson & Johnson has stopped the manufacturing and marketing of products containing talc powder -- which may be linked to serious health issues, including cancer,” Florida Attorney General Ashley Moody said in a statement.

"Companies cannot deceive people about the safety of the products they are selling,” North Carolina Attorney General Josh Stein said in a statement. “People need to have accurate information so they can buy the right products for their health.”

J&J stopped selling talcum-based baby powder globally last year, switching to corn starch as the main ingredient. The company still faces tens of thousands of talc lawsuits, and a class action lawsuit accuses company of hiding the dangers of talcum powder from shareholders, Reuters reported.

As of March 31, more than 61,000 were still suing J&J over talcum powder products. Most are women with ovarian cancer, while a smaller number had mesothelioma, a type of cancer linked to asbestos exposure, Reuters reported.

On May 1, J&J proposed a $6.48 billion settlement to resolve most of the litigation through a third bankruptcy filing. It has set aside an $11 billion reserve to cover all talc liabilities, Reuters reported.

“The company continues to pursue several paths to achieve a comprehensive and final resolution of the talc litigation,” Erik Haas, J&J's worldwide vice president of litigation, said in a statement.

Sources

  • Florida Attorney General, news release, June 12, 2024
  • Texas Attorney General, news release, June 12, 2024
  • North Carolina Attorney General, news release, June 12, 2024
  • Reuters

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-06-13 21:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords